Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

The Bull Case for Amprius Technologies Just Got Stronger

Authored by Thomas Hughes. Posted: 9/30/2026.

Amprius Technologies (NYSE: AMPX) just received a new $75 million Department of War (DoW) grant that completely changes the narrative and strengthens the bull case. In short, the funding shifts the company from a high-risk speculation with interesting technology to an in-demand supplier for government needs, with an accelerated timeline to profitability.

The grant mitigates concerns about dilution, Chinese and international manufacturing, and uncertain demand. It also helps answer key questions about how the company will secure contracts, whether it can achieve full compliance with the National Defense Authorization Act (NDAA), and how it will generate revenue. For the market, this means a shift in perspective: Investors will judge the company on milestones and execution rather than potential alone.

Amprius Technologies: Critical to the Drone Industry

The energy story near the Grand Canyon (Ad)

The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon.

A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.

See the company sitting on the biggest energy source on Earth

Amprius Technologies is in demand for its batteries, which offer superior energy density, discharge and recharge rates, and improved range and payload capacity for the vehicles they power. The grant, issued by the DoW Industrial Base Analysis and Sustainment Program, will help Amprius expand its manufacturing capacity. The company aims to retrofit an EV battery facility, in partnership with its South Korean manufacturing base, to produce batteries for Group 1–3 unmanned systems.

Group 1–3 unmanned systems include small tactical drones weighing less than 20 pounds, as well as larger unmanned aircraft such as Textron’s (NYSE: TXT) RQ-7B Shadow and Boeing’s (NYSE: BA) Integrator. With drones and unmanned systems now a focus for global military powers, Amprius is well-positioned to serve as a provider for the United States and its partners.

Analysts' responses to the news highlight a shifting narrative, with initial reactions reaffirming bullish sentiment and price targets. Colin Rusch of Oppenheimer says the news addresses a key concern about Amprius by allowing it to expand production capacity with relatively little of its own capital, while also highlighting the military’s urgent demand for advanced batteries. For investors, this strengthens conviction in the consensus sentiment and price targets, which are pegged at Moderate Buy and $22.09—more than 130% above the critical support target.

The Bottom Is In for Amprius Technologies

Amprius Technologies still has risks, but a lower stock price is near the bottom of the list. While short interest was high as of mid-September, the grant news will likely trigger short covering and attract institutional investors.

Institutions have been hesitant to invest in AMPX to date, but they can now give the stock more attention because the outlook has been significantly de-risked, including its solvency, capital structure, valuation and growth prospects. The likely outcome is that inflows begin soon and ramp over time as the company reports quarterly earnings and reaches its milestones. Even so, with nearly 500 institutions owning at least some shares as of late September, it won’t take much for this group to influence price action.

Amprius’ critical support target is near $9, coinciding with the 150-week EMA, a proxy for buy-and-hold investors, including institutions. Given the latest development, the stock is unlikely to break below that level and will likely produce rallies when it touches or crosses it. Indicators such as MACD and stochastic show a market ready to rebound, with stochastic already displaying a strong “Buy” signal near the bottom of its range.

Amprius Catalysts Versus Execution Risks

Amprius Technologies’ immediate catalyst, aside from the grant, is its upcoming Q3 earnings report. The Q2 release was excellent, including improved guidance and expectations that hypergrowth will continue. AMPX is likely to outperform as it provides more clarity on its next phase, strengthens market sentiment and prompts institutions to act. The report is due in early November; analysts forecast revenue growth of nearly 70%, with an inflection to profitability expected over the next two to three quarters.

Upcoming catalysts include several grant-related milestones. The deal is structured to reimburse the company for its investments, starting with retrofitting and retooling the existing line. After that, securing partner and in-kind contributions, obtaining NDAA compliance certification, beginning operations and ramping production will unlock additional funding. Over the long term, the deal aims to produce 12 million cells annually, with effective capacity across the target markets.

The biggest risk now is execution. While Amprius has proven it can deliver in small batches, scaling its South Korean contract-manufacturing footprint will be challenging, and delays or missteps will be reflected in the stock’s price. The grant does not eliminate this risk because Amprius will not own the new facility; one of its contract partners will. With this in play, short covering may begin, but that does not mean short sellers will exit. Most likely, they will simply reposition at higher levels until AMPX reaches its milestones.